Lung spheroid stem cells 100 million (DrugBank: -)
1 disease告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
85 | 特発性間質性肺炎 | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT04262167 (ClinicalTrials.gov) | October 22, 2020 | 6/2/2020 | Human Autologous Lung Stem Cell Transplant for Idiopathic Pulmonary Fibrosis | A Phase I, Randomized Study of the Safety and Efficacy of Intravenous Delivery of Lung Spheroid Stem Cells (LSCs) in Patients With Idiopathic Pulmonary Fibrosis | Idiopathic Pulmonary Fibrosis | Biological: Lung Spheroid Stem Cells 100 million;Biological: Lung Spheroid Stem Cells 200 million | University of North Carolina, Chapel Hill | National Heart, Lung, and Blood Institute (NHLBI) | Recruiting | 50 Years | 80 Years | All | 24 | Phase 1 | United States |